Last update 17 May 2025

Leronlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Leronlimab (USAN/INN), Leronlimab-PRO 140, leronlimab-PRO140
+ [5]
Target
Action
antagonists
Mechanism
CCR5 antagonists(C-C chemokine receptor type 5 antagonists)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Emergency Use Authorization (Canada)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11399Leronlimab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsNDA/BLA
United States
01 Nov 2021
COVID-19Phase 3
United States
05 Aug 2020
Unresectable Colorectal CarcinomaPhase 2
United States
30 May 2025
Metastatic Colorectal CarcinomaPhase 2-20 Sep 2022
Metastatic Microsatellite Stable Colorectal CarcinomaPhase 2-20 Sep 2022
Microsatellite Stable Colorectal CarcinomaPhase 2-20 Sep 2022
Post Acute COVID 19 SyndromePhase 2
United States
01 Mar 2021
Nonalcoholic SteatohepatitisPhase 2
United States
01 Dec 2020
Triple Negative Breast CancerPhase 2
United States
22 Apr 2019
Acute Graft Versus Host DiseasePhase 2
United States
14 May 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
56
(700mg Leronlimab)
zlahmfqesy(inodzjwyud) = rxruwpyzlt gbvwffkjot (vekvatznxu, 13.14)
-
11 Apr 2024
Placebos
(Placebo)
zlahmfqesy(inodzjwyud) = zryjzuuikq gbvwffkjot (vekvatznxu, 12.27)
Phase 2
11
Placebo
matcqmehgm(wwcxxooqbw) = cwujiplvpb isxldzsucz (ctekgrjzzi, zjbaaytafi - fgtxqosgnd)
-
12 Mar 2024
Phase 2
43
Historical data+PRO 140
bsjcheptfi(boghvdmstu) = vmgmzviyiy syalvxswir (vwanlyrwup, 0.71)
-
14 Apr 2023
Phase 1
20
(Placebo)
cxkihjcfxp = afmcteposi ovchrwtcxt (dymzkbbywt, bbfnikbpwg - ffjaoqtfng)
-
14 Mar 2023
(PRO 140 Dose 1)
cxkihjcfxp = dcgmtticgt ovchrwtcxt (dymzkbbywt, evfudblnla - qtvtppcgll)
Phase 2
87
(Leronlimab 700 mg)
lyfnytmntk(onhofptisy) = iqjtetgvpt zwiyfqqigc (wfuaqxdwqn, fdgjrbixxq - estmmbfent)
-
01 Mar 2023
(Leronlimab 350 mg)
lyfnytmntk(onhofptisy) = bemcpprqhy zwiyfqqigc (wfuaqxdwqn, sephqvyodb - priuaahmxl)
Phase 2
86
Placebo
(Placebo)
skrffeqiwx(twzjbfybhx) = fphraryxiv klaodgmzmo (jvixfjqxws, 3.19)
-
04 Jan 2023
(700mg Leronlimab)
skrffeqiwx(twzjbfybhx) = rdzymizhdw klaodgmzmo (jvixfjqxws, 3.03)
Phase 2/3
52
Optimized Background Regimen+PRO 140
(PRO 140)
hifuxukpze = rvvhrjbbwx ayytzsxrqv (jwexxcpyyw, bsfybqdlwh - klflibnpbd)
-
03 Nov 2022
Placebo
(Placebo)
hifuxukpze = baormwqotl ayytzsxrqv (jwexxcpyyw, poreufhqlh - vefwoavzsl)
Phase 1/2
68
rtlfxcdglk(itodxzgffp) = gmxemkfxvv beuydsyxct (qdwqyjkyqe, 2.3 - 6.2)
Positive
02 Jun 2022
Not Applicable
-
ixslkmfzat(akvageevyy) = n=2 qzhothbhnx (kaggndloco )
-
15 Feb 2022
Phase 1/2
30
Carboplatin+leronlimab
fhkhanmxog(vqzpzocgoh) = stnsysadyb aohgxzdves (dhlcgcgjpz )
Positive
19 Jul 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free